Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status:
Recruiting
Trial end date:
2023-12-15
Target enrollment:
Participant gender:
Summary
The proposed phase I/II study of disulfiram (DSF) for patients with presumed glioblastoma
multiforme (GBM) based on magnetic resonance imaging (MRI) or biopsy, including
administration before surgery and during adjuvant chemoradiotherapy. Patients will be treated
with 3 days of preoperative DSF/copper (Cu) prior to their surgery (or biopsy), which will be
followed by collection of tumor samples during surgery for analysis of drug uptake. After the
surgery, patients will receive standard radiation therapy (RT) and temozolomide (TMZ) with
the addition of concurrent DSF/Cu.